Back to Press-Releases

DIA Appoints Vivianna Guzman, MBA as New Chief Financial Officer

DIA Appoints New Chief Financial Officer

DIA, founded as the Drug Information Association, has named Vivianna Guzman, MBA, as Chief Financial Officer. In this capacity, Ms. Guzman is tasked with guiding DIA’s business performance and strategic risk processes. As an organization, DIA is the largest unique global, neutral, multidisciplinary forum for life science professionals to engage with key stakeholders.

Ms. Guzman comes to DIA after an impressive career that spans public accounting, for-profit industry and banking, and non-profit organizations. Having previously served as Chief Financial Officer for New York Public Radio (NYPR), Guzman led the financial strategic planning and day-to-day operation of the organization. Prior to joining NYPR, she spent more than 15 years as the Chief Financial Officer and, concurrently, the Head of Global Businesses for the American Management Association (AMA), a global leader in the Human Capital Development industry. In these roles, she provided global financial, operational, and strategic stewardship and held full P&L and Balance Sheet responsibility for all operations of AMA outside the United States including North America, Europe, Asia, and Middle East.

Ms. Guzman holds an MBA and a Bachelor of Science in Business Administration from the Universidad de Costa Rica.

“Ms. Guzman’s experience in strategic finance and operational excellence on a global scale comes at a critical time in the dynamic healthcare ecosystem globally,” said Barbara Lopez Kunz, Global Chief Executive, DIA. “I look forward to working with Vivianna to support and develop new infrastructure and create enhanced opportunities for growth and the positive impact we collectively have on patients.”

“Transformational change in nonprofit organizations is very exciting to me,” said Guzman. “A more digital, collaborative world presents greater opportunities not only for membership-driven organizations but for life sciences as a whole, and I’m very interested in furthering operational performance that will ultimately benefit the cause we are most committed to—better global health outcomes.”